RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group

Verena I. Gaidzik, Lars Bullinger, Richard F. Schlenk, Andreas S. Zimmermann, Jürgen Rock, Peter Paschka, Andrea Corbacioglu, Jürgen Krauter, Brigitte Schlegelberger, Arnold Ganser, Daniela Spath, Andrea Kundgen, Ingo G.H. Schmidt-Wolf, Katharina Gotze, David Nachbaur, Michael Pfreundschuh, Heinz A. Horst, Hartmut Dohner, Konstanze Dohner

Research output: Contribution to journalArticlepeer-review

249 Scopus citations


Purpose: To evaluate frequency, biologic features, and clinical relevance of RUNX1 mutations in acute myeloid leukemia (AML) Patients and Methods: Diagnostic samples from 945 patients (age 18 to 60 years) were analyzed for RUNX1 mutations. In a subset of cases (n = 269), microarray gene expression analysis was performed Results: Fifty-nine RUNX1 mutations were identified in 53 (5.6%) of 945 cases, predominantly in exons 3 (n = 11), 4 (n = 10), and 8 (n = 23). RUNX1 mutations clustered in the intermediate-risk cytogenetic group (46 of 640, 7.2%; cytogenetically normal, 34 of 538, 6.3%), whereas they were less frequent in adverse-risk cytogenetics (five of 109, 4.6%) and absent in core-binding-factor AML (0 of 77) and acute promyelocytic leukemia (0 of 61). RUNX1 mutations were associated with MLL-partial tandem duplications (P =.0007) and IDH1/IDH2 mutations (P =.03), inversely correlated with NPM1 (P <.0001), and in trend with CEBPA (P =.10) mutations. RUNX1 mutations were characterized by a distinct gene expression pattern; this RUNX1 mutation-derived signature was not exclusive for the mutation, but also included mostly adverse-risk AML [eg, 7q-,-7, inv(3), ort(3;3)]. RUNX1 mutations predicted for resistance to chemotherapy (rates of refractory disease 30% and 19%, P =.047, for RUNX1-mutated and wild-type patients, respectively), as well as inferior event-free survival (EFS; P <.0001), relapse-free survival (RFS, P =.022), and overall survival (P =.051). In multivariable analysis, RUNX1 mutations were an independent prognostic marker for shorter EFS (P =.007). Explorative subgroup analysis revealed that allogeneic hematopoietic stem-cel transplantation had a favorable impact on RFS in RUNX1-mutated patients (P <.0001) Conclusion: AML with RUNX1 mutations are characterized by distinct genetic properties and are associated with resistance to therapy and inferior outcome

Original languageEnglish
Pages (from-to)1364-1372
Number of pages9
JournalJournal of Clinical Oncology
Issue number10
StatePublished - 1 Apr 2011


Dive into the research topics of 'RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML study group'. Together they form a unique fingerprint.

Cite this